Malignant tumors, heart disease, cardiovascular and cerebrovascular diseases are becoming "killers" that threaten health, and in the clinic, when treating patients with these diseases, it is necessary to establish a "cardiovascular pathway".
However, there are three major clinical challenges in the establishment of traditional vascular pathways: difficult puncture, poor localization, and multiple complications. Professor Zhang Haijun, deputy director of the Institute of Interventional Vascular Research of Tongji University, and his team created the cardiovascular precision localization diagnosis and treatment system, successfully breaking through the above clinical challenges.
In 2021, the project "Establishment of Key Technology System for Digital Diagnosis and Treatment of Vascular Pathways and Its Clinical Application" led by Zhang Haijun won the second prize of the 2020 National Science and Technology Progress Award.
The project led by Zhang Haijun won the second prize of the 2020 National Science and Technology Progress Award The pictures in this article are all provided by Tongji University
The international first established a diagnosis and treatment system for the precise positioning of the middle and cardiovascular diseases
The doctors of the Tenth People's Hospital affiliated to Tongji University were pleased to find that when performing operations such as cardiovascular and cerebrovascular emergency treatment and tumor chemotherapy, it is easy to establish a cardiovascular pathway with only one machine.
This artifact is the central vascular precision positioning diagnosis and treatment system developed by Zhang Haijun's team. When establishing the cardiovascular pathway, the system can realize intelligent analysis and screening of blood vessels, real-time monitoring of the whole process of puncture from the body surface to the target blood vessels, catheter sensing and transmission of bioelectricity, alternative X-ray positioning to reduce the error of the positioning system, and establish a blind spot-free plane puncture.
Zhang Haijun introduced that when clinically implementing diagnosis and treatment operations such as cardiovascular and cerebrovascular severe emergency, tumor chemotherapy and parenteral nutrition, the establishment of cardiovascular pathways is a prerequisite. Every year, nearly 20 million cases of cardiovascular pathways are established in the world, and nearly 5 million cases are established in China, ranking second in the world. However, the establishment of the cardiovascular pathway faces three major clinical challenges: difficult puncture, poor localization, and many complications. Specifically, traditional methods have operational risks such as puncturing blood vessels, mistakenly penetrating nerves, penetrating the pleura, etc., and complications such as bleeding, hematoma, vascular perforation, hemopsyothorax, tracheal compression, atrial fibrillation, phlebitis and even pulmonary artery embolism may occur.
For the new cardiovascular access technology system, the major hospitals across the country have responded warmly: they can assess blood vessels, measure blood flow speed, correctly select puncture sites, accurately navigate the body, integrate operations, and reduce side effects...
Innovative breakthroughs are inseparable from the dedicated research of Zhang Haijun and the team, who aim at the world's cutting-edge technology, after more than 10 years of medical-engineering cross-cutting and clinical translational research, create a new cardiovascular pathway technology system, and complete a series of medical devices independent research and industrialization.
Nowadays, the project of "Establishment of Key Technical System for Digital Diagnosis and Treatment of Vascular Access and Its Clinical Application" has obtained 26 national authorized invention patents, 11 national medical device registration certificates, and 4 industry standards; published more than 200 high-level papers, edited 3 academic monographs, and led the publication of 1 clinical expert consensus.
The results have been promoted to more than 1,000 hospitals across the country, reducing complications and medical costs for patients; breaking the technology monopoly of products, replacing imports and exporting to 30 countries and regions; building a national engineering laboratory and incubating 2 national high-tech enterprises.
Zhang Haijun (center) and team
Dream of realizing the localization of high-end medical devices
This is not the first innovation on the road of Zhang Haijun's medical device research and development, what is the driving force for continuous innovation and continuous breakthroughs?
"The research and development of medical devices must be oriented to the major needs of the country and the life and health of the people." Zhang Haijun said that the localization of medium-to-high-end medical devices is his "small" Chinese dream.
The 53-year-old Zhang Haijun has a rich experience and a ten-year medical education and clinical background, after graduation engaged in medical research and clinical work in hospitals, and later joined a Multinational Company in Germany to engage in research and development and management.
"The domestic high-end medical device market has always been monopolized by large foreign companies." In this regard, Zhang Haijun hopes to make some changes.
He traveled to the United States and Denmark to learn international advanced medical technology. At the end of his studies, he refused the high salaries of many multinational companies and universities, resolutely returned to China, and opened the road of independent research and development of medical devices.
Interventional catheter is an indispensable common medical device in the chemotherapy process of tumor patients, the clinical use is very large, but the seemingly inconspicuous small catheter has been monopolized by foreign products until 2011.
Determined to develop his own products, Zhang Led the team through thousands of material process optimization experiments to finally overcome this problem. In July 2011, the team obtained the first domestic peripheral center intravenous interventional catheter (PICC) product registration certificate, completed the localization of PICC products, product performance is better than imported products, filling the domestic gap, clinical use effect is good.
In April 2012, the coronary drug coating stent system developed by Zhang Haijun's team was certified, and it has independent intellectual property rights in key technologies such as drug coating and coating, and successfully applied for PCT international patent protection in the United States, Europe and Japan.
The ultrasonic controlled-release drug balloon led by Zhang Haijun has passed the special review of national innovative medical devices, undertaken the research and development of degradable zinc alloy intravascular stents, and will soon carry out the world's first clinical trial of zinc alloy stents in human applications.